Searchable abstracts of presentations at key conferences in endocrinology

ea0081rc3.6 | Rapid Communications 3: Thyroid 1 | ECE2022

The mRNA of fibronectin 1 and of the integrin subunit alpha V are powerful prognostic indicators in papillary thyroid carcinoma

Vitale Mario , Marotta Vincenzo , Tortora Anna , Izzo Giulia , Rocco Domenico

Integrins are cell-extracellular matrix adhesion molecules considered functionally related to the development of cancer metastasis. Starting from the dataset of mRNA-seq of papillary thyroid carcinoma (PTC) from the TCGA, we determined the expression of fibronectin 1 (FN1) and fibronectin-binding integrins in PTC. We then analyzed the association of the expression of these two genes with the driver genes, the stage of the disease and its outcome. 355 PTCs and 58 normal thyroid...

ea0081p394 | Environmental Endocrinology | ECE2022

Synergism between bisphenol a exposure and overweight/obesity in increasing the malignancy risk in a cohort of patients with thyroid nodules

Marotta Vincenzo , Grumetto Lucia , Neri Ilaria , Russo Giacomo , Tortora Anna , Izzo Giulia , Rocco Domenico , Vitale Mario

Introduction: The plasticizer Bisphenol A (BPA) is an endocrine disruptor with thyroid interfering activity. Obesity is a recognized risk factor for thyroid cancer. A recent study showed that subjects with BMI ≥ 25 are more prone to BPA-related thyroid disruption. To date, few and controversial experimental and epidemiological data provide weak evidence about a correlation between BPA exposure and thyroid cancer development. Aim of the present study was to assess a possi...

ea0081ep789 | Pituitary and Neuroendocrinology | ECE2022

GH provocative tests stimulate the growth in children without GH deficiency

Tortora Anna , Marotta Vincenzo , Izzo Giulia , Rocco Domenico , Clemente Gennaro , Vitale Mario

Introduction: GH deficiency (GHD) is a clinical disorder characterized by pathological short stature in the child, altered body composition, impaired psychological well-being and reduced quality of life. These alterations are almost always reversible after recombinant human GH (rhGH) administration, which is currently the only accepted treatment for the subjects with GHD. Secretory dysfunction is confirmed when GH peak does not reach the established cut-off in at least two dif...

ea0032s31.3 | Clinical impact of rare mutations in endocrinology | ECE2013

Genetic diagnosis of hereditary neuroendocrine syndrome in asyntomatic patients: clinical and prognostic implications

Faggiano Antongiulio , Ramundo Valeria , Marciello Francesca , Del Prete Michela , Marotta Vincenzo , Colao Annamaria

Neuroendocrine tumours (NETs) can be sporadic or can arise in complex hereditary endocrine disorders such as multiple endocrine neoplasias (MENs), familial paragangliomatosis (FPGLs), neurofibromatosis type 1 (NF1), von Hippel–Lindau disease (VHL), tuberous sclerosis (TSC). It has been estimated that hereditary NET occurrence varies with site of origin of the tumour, representing 5–30% of all cases of NET. These rates seems to be an underestimation and novel mutation...

ea0049ep1407 | Thyroid (non-cancer) | ECE2017

Histologically-proven Hashimoto’s thyroiditis significantly decreases the risk of structural recurrence in patients with low risk intra-thyroidal papillary thyroid cancer

Marotta Vincenzo , Sciammarella Concetta , Chiofalo Maria Grazia , Gambardella Claudio , Bellevicine Claudio , Grasso Marica , Conzo Giovanni , Botti Gerardo , Losito Simona , Troncone Giancarlo , Pezzullo Luciano , Colao Annamaria , Faggiano Antongiulio

Introduction: Due to the absence of randomized controlled trials, management of low risk papillary thyroid cancer (PTC), which represents the most commonly diagnosed form of thyroid malignancy, remains controversial. Hashimoto’s thyroiditis (HT) is significantly more frequent in patients with PTC, as compared with subjects carrying benign lesions as well as different tumour histotypes. Despite still controversial, HT is considered a protective factor in PTC being associat...

ea0037ep1132 | Endocrine tumours | ECE2015

High-dose treatment with somatostatin analogues in neuroendocrine tumours

Modica Roberta , Ramundo Valeria , Marciello Francesca , Marotta Vincenzo , Pizza Genoveffa , Carratu Anna Chiara , Roseto Chiara de Luca di , Buonomano Pasqualina , Giordano Carla , Trimarchi Francesco , Colao Annamaria , Faggiano Antongiulio

Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical. Aim of this study is to evaluate efficacy and safety of high-dose SSA treatment in patients with progressive disease under standard SSA dose. Twenty-one patients (median age 56.8 years) with NET of different orig...

ea0035p534 | Endocrine tumours and neoplasia | ECE2014

Role of metformin on recurrence-free survival in neuroendocrine tumors

Marciello Francesca , Modica Roberta , Marotta Vincenzo , Ramundo Valeria , Prete Michela Del , Buonomano Pasqualina , Carratu Anna Chiara , de Luca di Roseto Chiara , Picillo Ester , Colao Annamaria , Faggiano Antongiulio

Introduction: Recent data suggest that metformin has antineoplastic properties in different type of cancer. Effects of metformin have never been investigated in neuroendocrine tumors (NET).We aim to determine the role of metformine on recurrence-free survival (RFS) in NET patients.Materials and methods: A retrospective analysis was conducted comparing NET patients with recent diagnosis (<3 year) of diabetes mellitus (with HbA1c...

ea0032p115 | Calcium and Vitamin D metabolism | ECE2013

Cinacalcet in patients with primary hyperparathyroidism (PHPT): comparison between sporadic and MEN1 PHPT

Prete Michela Del , Marotta Vincenzo , Ramundo Valeria , Marciello Francesca , Carratu Anna Chiara , di Roseto Chiara De Luca , Esposito Raffaella , Di Sarno Antonella , Colao Annamaria , Faggiano Antongiulio

Introduction: PHPT is a common endocrine disease characterized by hypercalcemia and different degree of osteoporosis and nephrolithiasis. PHPT arises in the context of an inherited disease in 5% of cases. Multiple endocrine neoplasia type 1 (MEN1) is the commonest cause of inherited PHPT. The main therapeutic approach for PHPT is surgery, however many patients refuse or have contraindications for surgery while others, in particular those with MEN1 PHPT, have persistent/relapsi...

ea0032p520 | Endocrine tumours and neoplasia | ECE2013

Assessment of fatal events in patients with radio-active iodine (RAI)-refractory differentiated thyroid cancer responsive to treatment with sorafenib

Marotta Vincenzo , Del Prete Michela , Ramundo Valeria , Marciello Francesca , Di Sarno Antonella , Esposito Raffaella , Carratu Annachiara , de Luca di Roseto Chiara , Camera Luigi , Colao Annamaria , Faggiano Antongiulio

Introduction: Targeted therapy with the multi-kinase inhibitor sorafenib is effective for treatment of differentiated thyroid cancer (DTC) unresponsive to RAI. Although kinase-inhibitors (KIs) are usually well tolerated, severe and even fatal adverse events are reported. Aim of the study was to assess incidence and characteristics of fatal events in patients with RAI-refractory DTC responsive to treatment with sorafenib.Design: A retrospective analysis o...

ea0032p529 | Endocrine tumours and neoplasia | ECE2013

Familial malignant paraganglioma is long-term stabilized with the tyrosine-kinase inhibitor sunitinib

Ramundo Valeria , Marciello Francesca , Del Prete Michela , Marotta Vincenzo , Esposito Raffaella , Chiara Carratu Anna , de Luca di Roseto Chiara , Colao Annamaria , Faggiano Antongiulio

Introduction: Paragangliomas are neuroectodermal tumors that arise from adrenal medulla or extra-adrenal ganglia and are characterized by high vascularisation. A high rate of these tumours is genetically inherited. For malignant paragangliomas, chemo- and radio-therapy are potentially effective, but tumor response is of short duration and patient prognosis is quite poor. Sunitinib is a tyrosine-kinase inhibitor, targeting VEGFR1, -2, PDGFRα, -β, RET and c-Kit. Recent...